Hamps Bio Limited reported a consolidated net loss of ₹73.87 lakh for the financial year ended March 31, 2026, compared to a net profit of ₹29.77 lakh in the previous year. The company's board approved the audited standalone and consolidated financial results for the half-year and year ended March 31, 2026, at a meeting held on May 29, 2026. Revenue from operations for the year increased to ₹880.67 lakh from ₹681.98 lakh in FY25. The statutory auditor, MGHVS & Associates, issued an unmodified opinion on the financial results.

The standalone financial results showed a net loss of ₹65.49 lakh for FY26, a significant decline from the net profit of ₹29.77 lakh recorded in the previous year. Total income for the standalone entity rose to ₹884.86 lakh from ₹681.98 lakh in the prior year. The board also approved the appointment of Naviwala & Associates, Surat, as the internal auditor for the financial year 2026-2027, effective from May 29, 2026.

Financial Performance

The company's total expenses increased to ₹950.65 lakh in FY26 from ₹641.60 lakh in the previous year. Finance costs for the year stood at ₹24.88 lakh, while depreciation and amortization expenses were ₹81.68 lakh. The basic earnings per share (EPS) for the year was reported at (₹0.85), compared to ₹0.68 in FY25. The company issued bonus shares in the ratio of 1:1 during the year, and EPS figures have been adjusted retrospectively.

Consolidated vs Standalone Results

The consolidated results include the financials of HSDL Innovative Private Limited, which became a wholly owned subsidiary on March 25, 2026. Consequently, the comparative figures for the previous year represent standalone figures of the parent company. The consolidated revenue from operations for FY26 was ₹847.46 lakh, with a total income of ₹880.67 lakh. The consolidated net loss after tax for the year was ₹73.87 lakh.

Key Financial Metrics

The intimation was submitted to BSE Limited in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting commenced at 4:00 PM IST and concluded at 6:30 PM IST.

Hamps Bio Limited has successfully obtained its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate demonstrates the company's adherence to regulatory requirements governing share depositories and participant operations.

Regulatory Compliance Status

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA), issued the certificate on April 04, 2026. The certificate confirms that Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 is not applicable to Hamps Bio Limited during the specified quarter.

Share Holding Structure

The certificate highlights that the entire shareholding of Hamps Bio Limited remains in dematerialised (demat) form. This complete dematerialisation of shares eliminates the need for physical share certificates and ensures seamless electronic trading and transfer of securities.

During the quarter ended March 31, 2026, Bigshare Services Private Limited confirmed that no requests for rematerialisation were received from any company members. This indicates investor satisfaction with the electronic format and smooth functioning of the depository system.

Corporate Communication

Company Secretary Komal Jain (Membership No. ACS A40470) formally communicated the certificate to BSE Limited on April 14, 2026. The company has also made the certificate available on its official website at www.hampsbio.com for stakeholder access and transparency.

Company Operations

Hamps Bio Limited operates manufacturing facilities at two locations in Gujarat. Unit-1 is situated at G.I.D.C. Industrial Estate near Atul Ltd. in Ankleshwar, while Unit-2 is located at Bhatpore G.I.D.C. in Surat. The company, previously known as Hamps Bio Pvt. Ltd., maintains its corporate identification number as L24233GJ2007PLC049692.